 GERMANTOWN, Md., Oct. 1, 2021 PRNewswire -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. Nasdaq: PGEN, today announced additional positive interim data from the ongoing Phase 1b2a clinical study investigating AG019 ActoBioticsTM for the treatment of recent-onset type 1 diabetes T1D clinical trial identifier: NCT03751007, EudraCT 2017-002871-24. 